Posted by Michael Wonder on 27 Mar 2025
ICER publishes evidence report on treatment for retinitis pigmentosa
26 March 2025 - There are significant uncertainties regarding long term efficacy and durability of sonpiretigene isteparvovec; ICER estimates that treatment would achieve common thresholds of cost-effectiveness if priced between $67,400 and $101,300.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec (Nanoscope Therapeutics) for the treatment of advanced retinitis pigmentosa.
